Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CRTX - Alzheimer's - Cassava Cortexyme Or Anavex: Who Will Come On Top?

CRTX - Alzheimer's - Cassava Cortexyme Or Anavex: Who Will Come On Top?

Cortexyme Inc.
  • Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
  • Cortexyme failed to prevent disease progression in 50% of patients on what was hopefully an upstream mechanism of action vs. Simufilam.
  • The CTAD Conference in November will shed much light on the most recent clinical data of Anavex, Cassava Sciences and Cortexyme.
  • The future of Alzheimer's treatments will probably consist of a combination of treatments to maximize results as in oncology.
  • On November 4, 2021, Cassava Sciences announced no wrongdoing was found by the American Journal of Neuroscience on its data.

For further details see:

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Stock Information
Company Name: Cortexyme Inc.
Stock Symbol: CRTX
Market: NYSE
Website: cortexyme.com
Menu
CRTX CRTX Quote CRTX Short CRTX News CRTX Articles CRTX Message Board
Get CRTX Alerts

News, Short Squeeze, Breakout and More Instantly...